March 18, 2024 4:54pm

A scorecard of earnings releases of covered companies - 

The current LPS (loss per share) or net income, cash positions i.e. "runways" is a reflection of this universe's investing "status".

26 of 35 covered released to date

 

 


COMPANY 

SYMBOL

NET

INCOME

Q4/23 LOSS & LPS

FY/23 LOSS

or Net Income

LPS

 CASH POSITION RUNWAY

 

Blueprint

Medicine

 

BPMC

 

-$110.9 M

-$1.82 pre-share

-$570 M

-$8.37 per share

$767.2 M 2026

Agenus

 

AGEN

 

 

-$48.5 M

-$0.13 per share

-$257.4 M

-$0.69 per share

$76.1 M

+$25 M (BMS)

Potential $100-$200 M

2025

Alnylam

Pharmaceuticals

ALNY

 

 

-$96.6 M

-$1.10 per share

-$202.618 M

-$3.52 per share

$2.44 B

2027

Prime Medicine

 

PRME

 

Hiding Them

-$198. 1 M

-$2.18 per share

$138.2 M

Raised 2/24 $161 M

2026

Adverum

Biotechnologies

ADVM

 

 

-$23.7 M

-$0.33 pre share

-$32.7 M

-$0.33 per share

$96.5 M

Offering 2/24/23

$127.5 M

Q4/25

Compass

Therapeutics

 

CMPX

 

 

     

AxoGen

AXGN

 

 

-$3.9 M

-$0.09 per share

-$21.7 M

-$0.57 per share

$37 M

2026

Revenue 

projection 

$177-$181 M 

in 2024

Bellicum

Pharmaceuticals

BLCM

 

 

 

     

Beam

Therapeutics

BEAM

Q4/23

+$142.8 M

+$177 per share

 

-$132.5 M

-$1.72 per share

$1.2 B 2027

BioLife

Solutions

BLFS

 

 

-$13.38 M

-$0.30 per share

-$66.42 M

-$1.52 per share

$52.3 M 2026
Harvard Apparatus RT

HRGN

 

 

     

bluebird bio

 

BLUE

 

 

 

     

Brainstorm Cell Therapeutics

 

BCLI  

 

     

Caribou

Biosciences 

CRBU  

-$34.5 M

-$0.39 per share

-$102.1 M

-$1.38 per share

$372.4 M Q1/26
Cellectis SA

CLLS

 

 

 

     

CRISPR

Therapeutics

CRSP

 

+$89.3 M

+$1.10 per share

 

-$136,650 M

-$1.95 per share

$1,695,7 M 2027

Editas

Medicine

EDIT

 

 

-$18.9 M

-$0.23 per share

-$153.2 M

-$2.02 per share

$427 M

2026

Fate

Therapeutics

FATE

 

 

-$44.1 M

-$0.45 per share

-$169.9 M

-$1.64

$316.2 M early 2025

Graphite

Bio

GRPH

 

 

     

Homology

Medicine

FIXX

 

       

Intellia

Therapeutics

NTLA

 

 

-$132.2 M

-$1.46 per share

-$481.19

-$5.42 per share

$1 B mid 2026

Precigen

PGEN

 

 

 

 

     

Ionis

Pharmaceuticals

IONS

 

 

 

 

   

 

Mesoblast

MESO

 

 

Hiding them

-$32,5 M

-$3.82 per share

$77.6 M

<-$6.9 M in

financing cost>

2025
MiMedx Group

MDXG

 

+$53 M

+$0.32 per share

 

 

FY23

'Net Income

+$58.22

+0.37

$82 M

2025

 

Verve

Therapeutics

VERV  

-$48.4 M

-$0.69 per share

-$200.1 M

-$3.12 per share

$624 M 2026

Regenxbio

 

RGNX

 

 

-$62.9 M

-$1.43 per share

-$263.5 M

-$6.02 per share

$314 M Q2/2025

Sage

Therapeutics

SAGE

 

 

-$32.7 M

-$0.55 per share

-$541.5 M

-$9.05 per share

$753 M

2026

Sangamo

Biosciences

SGMO

 

 

-$60.3 M

-$0.34 per share

-$257.8 M

-$1.48 per share

$81 M Q3/24

Solid

Biosciences

SLDB

 

 

-$20.3 M

Hiding per share

-$96 M

-$4.83

$123.6 M

$108.9 M raised 1/24

2026

Ultragenyx

Pharmaceuticals

RARE  

-$123.19 M

-$1.52 per share

-$606, 639 M

-$8.25

$777 M 2025

uniQure N.V.

 

QURE

 

 

Hiding them

-$308.5 M

-$6.47 per share

$617.9 M 2025

Generation

Bio

GBIO

 

-$35.2 M

-$o,53

-$126.6 M

-$1.96

$264.4 M 2H/2027

Vericel

 

VCEL

 

+$13 M

+$0.26 per share

 

FY23

Net Loss

-$3.2 M

-$0.07 per share

$152.6 M

2027

Voyager

Therapeutics

VYGR

 

+$56.4 M

+$1.28 per share

 

FY23

Net Income

+$32.3 M

+$3.08

Close of '23 = $230.9 M

Current: $431 M

2027